Jim Cramer recently discussed Bristol-Myers Squibb Company (BMY), praising its COBENFY schizophrenia drug. However, he changed his tune, emphasizing the drug’s importance for BMY’s success. Cramer previously mentioned BMY’s “faint pulse” in the market. While BMY has potential, consider AI stocks for higher returns with limited downside risk. Check out the best short-term AI stock for more insights.

Read more at Yahoo Finance: All Or Nothing With A Breakthrough Drug, Says Jim Cramer